Gilead Sciences begins two Phase 3 Studies of remdesivir to treat COVID-19
US-based biotechnology firm Gilead Sciences has initiated two Phase 3 clinical trials to evaluate the safety and efficacy of remdesivir in adults diagnosed with the novel coronavirus (COVID-19).